Callisto BioMed is redefining cardiovascular risk prediction and delivering over 85% specificity - as opposed to below 50% for a standard lipid profile. Our LipoSpec micro-fluidic platform delivers a fully automated read-out of all five HDL subclasses (including HDL-2b) and sdLDL from a 5 µL finger-stick in under 90 seconds. Already NMPA-cleared and used in 20+ hospitals, testing in a CLIA certified lab in Boston has begun and FDA clearance is the next important milestone.

Why it matters – specific HDL sub-fractions predict coronary events 30 % better than total HDL-C, yet routine lipid panels ignore them.

Partner value:

• Pharma/Biotech – turnkey companion & stratification test for HDL/LDL targeting drugs.

• IVD Labs – desktop analyzer runs 96 samples in < 2 h.

• Investors – consumable model projected to exceed 1 M tests/year by Year 4 at > 60 % gross margin; raising US $5 M Series A.

Meet co-founder Odilo Mueller, PhD at BIO to shape the future of preventive cardiology.